DOCSLIB.ORG

Program Book Welcome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Program Book Welcome North Central Section of the AUA, Inc. 92nd Annual Meeting September 5 - 8, 2018 Fairmont Chicago, Millennium Park Chicago, Illinois PROGRAM BOOK WELCOME Table of Contents Schedule at a Glance 2 Hotel Directory 6 Promotional Partners 7 Exhibitors 8 Industry Satellite Symposium Events 9 CME Information 10 2017 - 2018 Board of Directors 13 2017 - 2018 Committee Listing 14 NCS Representatives to AUA Committees 17 Past Presidents and Annual Meeting Sites 18 Board of Directors and Committee Meetings 21 General Meeting Information 22 Evening Functions 23 Speaker Information 24 Program 25 Wednesday, September 5 25 Thursday, September 6 29 Friday, September 7 50 Saturday, September 8 67 Participant Index 78 Podiums 87 Posters 190 Annual Business Meeting Agenda 223 Membership Candidates and Transfers 224 Membership Summary Report 225 Proposed Bylaws Changes 226 Bylaws 228 In Memoriam 240 Award Recipients 241 NCS Urology Residency Programs 247 AUA Officers 250 AUA Foundation Research Scholars 250 POLICY: Filming, Photography, Audio Recording, and Cell Phones No attendee/visitor at the NCS 92nd Annual Meeting may record, film, tape, photograph, interview, or use any other such media during any presentation, display, or exhibit without the express, advance approval of the NCS Executive Director. The policy applies to all NCS members, nonmembers, guests, and exhibitors, as well as members of the print, online, or broadcast media. Back to Table of Contents 1 Schedule at a Glance WEDNESDAY, SEPTEMBER 5, 2018 7:00 a.m. - 5:30 p.m. Registration/Information Desk Hours: International Foyer 7:00 a.m. - 5:30 p.m. Speaker Ready Room Hours: Royal Room 7:30 a.m. - 11:00 a.m. Spouse/Guest Hospitality Suite Hours: Embassy Room 7:30 a.m. - 8:30 a.m. Breakfast: International Foyer 6:30 p.m. - 8:30 p.m. Welcome Reception in Exhibit Hall: Imperial Ballroom 8:00 a.m. Robotic Urologic Surgery: Technique and Troubleshooting- A Video Session with Panel Discussion: International Ballroom 9:30 a.m. Defining the Opioid Epidemic and Its Implications for Prescribing Practices in Urology: International Ballroom 10:30 a.m. ABU Update: International Ballroom 10:40 a.m. Break: International Foyer 11:00 a.m. AUA Course of Choice Lecture - AUA Guidelines 2017: Non-Muscle Invasive Bladder Cancer: International Ballroom 12:00 p.m. Lunch: International Foyer 1:15 p.m. Health Policy and Practice Primary Care Update in Urology: Management: Gold Room International Ballroom Back to Table of Contents 2 THURSDAY, SEPTEMBER 6, 2018 6:00 a.m. - 5:30 p.m. Registration/Information Desk Hours: International Foyer 6:00 a.m. - 5:30 p.m. Speaker Ready Room Hours: Royal Room 7:00 a.m. - 4:30 p.m. Exhibit Hall Hours: Imperial Ballroom 7:30 a.m. - 11:00 a.m. Spouse/Guest Hospitality Suite Hours: Embassy Room 6:00 p.m. - 7:00 p.m. Young Urologists Mixer: Regent Room 6:30 a.m. Video Session I: Adrenal/ Kidney/ Ureter - Gold Room Malignant Podium Session: International Ballroom 7:30 a.m. Break - Visit Exhibits: Imperial Ballroom 8:00 a.m. President's Welcome: International Ballroom 8:05 a.m. State-of-the-Art Lecture: Treatment of Priapism: International Ballroom 8:40 a.m. State-of-the-Art Lecture: New Devices and Technologies for OAB Management: International Ballroom 9:15 a.m. Panel Discussion: Controversies in Pediatric Urology: International Ballroom 10:00 a.m. Advances in Bladder Cancer: Making Real Progress in 2018: International Ballroom 10:30 a.m. Break - Visit Exhibits: Imperial Ballroom 11:00 a.m. Panel Discussion: Prostate Cancer: International Ballroom 12:00 p.m. Industry Sponsored Lunch Industry Sponsored Lunch Symposium: Symposium: Crystal Room Regent Room 1:15 p.m. Case Discussion: Urolithiasis Case Panel: International Ballroom 2:00 p.m. Pediatric Podium Endourology/ Stone Socioeconomics/ Session: Rouge Disease I Podium Health Policy & Room Session: Gold Room Outcomes Research Podium Session: International Ballroom 3:00 p.m. State-of-the-Art Lecture: Innovations in Renal and Ureteral Stone Management: International Ballroom 4:00 p.m. Break - Visit Exhibits: Imperial Ballroom 4:30 p.m. Prostate Penis/ Urethra/ Pediatrics Patient Safety, Malignant I Testis/ Poster Quality Podium Scrotum - Session: State Improvement Session: Benign/ Room Initiatives & International Malignant Outcomes Ballroom Podium Research Session: Gold Poster Room Session: Ambassador Room Back to Table of Contents 3 FRIDAY, SEPTEMBER 7, 2018 6:00 a.m. - 5:30 p.m. Registration/Information Desk Hours: International Foyer 6:00 a.m. - 5:30 p.m. Speaker Ready Room Hours: Royal Room 7:00 a.m. - 11:00 a.m. Exhibit Hall Hours: Imperial Ballroom 7:30 a.m. - 11:00 a.m. Spouse/Guest Hospitality Suite Hours: Embassy Room 6:00 p.m. - 7:30 p.m. President's Reception: Rouge Room 6:30 a.m. Video Session II: Male and Couple Infertility/ Gold Room Sexual Dysfunction Podium Session: International Ballroom 7:30 a.m. Break - Visit Exhibits: Imperial Ballroom 8:00 a.m. State-of-the-Art Lecture: Prostate Cancer Revisited: International Ballroom 8:45 a.m. Panel Discussion: Infertility: International Ballroom 9:30 a.m. Break - Visit Exhibits: Imperial Ballroom 10:00 a.m. NCS Resident Bowl: Round 1: International Ballroom 10:45 a.m. Women in Young Prostate Adrenal/ Urology Urologists Malignant II Kidney/ Ureter Session: Gold Speed Podium - Benign/ Room Mentoring Session: Malignant Program: International Poster Chancellor Ballroom Session: Room Ambassador Room 12:00 p.m. Industry Sponsored Lunch Industry Sponsored Lunch Symposium: Symposium: Crystal Room Regent Room 1:15 p.m. NCS Faculty Lecture: Testosterone-What's The Fuss?: International Ballroom 1:55 p.m. AUA Update: International Ballroom 2:10 p.m. Report from the NCS AUA Foundation Scholar: International Ballroom 2:20 p.m. Award Presentation: John D. Silbar, Thirlby and Traveling Fellowship: International Ballroom 2:25 p.m. Presidential Address: The Importance of Mentors and Mentoring: International Ballroom 3:00 p.m. Annual Business Meeting: International Ballroom 3:45 p.m. Panel Discussion: Urologic Reconstruction: International Ballroom 4:30 p.m. Bladder Laparoscopy/ Endourology/ Prostate Malignant Robotics Stone Disease Malignant Podium Podium Poster Poster Session: Gold Session: Session: State Session: Room International Room Ambassador Ballroom Room Back to Table of Contents 4 SATURDAY, SEPTEMBER 8, 2018 6:30 a.m. - 8:00 a.m. Breakfast: International Foyer 6:30 a.m. - 12:00 p.m. Registration/Information Desk Hours: International Foyer 6:30 a.m. - 12:00 p.m. Speaker Ready Room Hours: Royal Room 7:30 a.m. - 11:00 a.m. Spouse/Guest Hospitality Suite Hours: Embassy Room 7:00 a.m. Patient Safety & Endourology/ Stone 7:30 a.m. - 8:00 a.m. Quality Improvement Disease II Podium Initiatives Podium Session: Gold Room Trauma/ Transplant Session: Rouge Podium Session: Room International Ballroom 8:00 a.m. Roundtable Discussion: Future of Urology: International Ballroom 9:00 a.m. Bizarre and Interesting Cases Podium Session: International Ballroom 9:45 a.m. Break: International Foyer 10:00 a.m. Urinary Incontinence/ Prostate Benign/ Malignant Neurourology Podium Session: Podium Session: Gold Room International Ballroom 10:45 a.m. NCS Resident Bowl Finals: International Ballroom 11:45 a.m. Best Poster, Best Video, and Bizarre & Interesting Case Award Presentations: International Ballroom 11:50 a.m. Incoming NCS President Remarks: International Ballroom Back to Table of Contents 5 Hotel Directory General Session: International Ballroom (2nd floor) Breakout Rooms: Gold Room (2nd floor) Rouge Room (lobby level) Exhibit Hall: Imperial Ballroom (B2 level) Industry Sponsored Symposium Events: Crystal Room (3rd floor) Regent Room (3rd Floor) Poster Sessions: Ambassador Room (2nd floor) State Room (2nd floor) Speaker Ready Room: Royal Room (B2 level) Spouse/Guest Hospitality Suite: Embassy Room (2nd floor) Committee Meetings: Regal Room (B2 level) Chancellor Room (3rd floor) Back to Table of Contents 6 Promotional Partners NCS recognizes and welcomes our 2018 Promotional Partners (as of 8/28/2018) Platinum Partners Astellas Pharma and Pfizer Oncology Genomic Health Janssen Biotech, Inc. Merck & Co., Inc. Silver Partners Astellas Pharma US, Inc. Avadel Pharmaceuticals Bayer Healthcare Endo Pharmaceuticals Lumenis, Inc. Marley Drug, Inc Myriad Genetic Laboratories, Inc. University Compounding Pharmacy of Michigan Back to Table of Contents 7 Exhibitors Thank you to our 2018 Exhibitors (as of 8/28/2018) AbbVie Janssen Biotech Allergan, Inc. KARL STORZ American Urological Association, Inc. Koelis Antares Pharma LABORIE Astellas Pharma and Pfizer Oncology Liebel-Flarsheim, a Guerbet Company Astellas Pharma US, Inc. LithoLyte Augmenix Lumenis, Inc. Avadel Pharmaceuticals Marley Drug, Inc Bayer Healthcare MDxHealth BK Ultrasound Medispec, Ltd. Blue Earth Diagnostics, Inc Medtronic, Inc. Boston Scientific Corporation Merck & Co., Inc. Coloplast Myriad Genetic Laboratories, Inc. Cook Medical NeoTract Teleflex Creative Medical Technologies NextMed, LLC Dendreon Pharmaceuticals LLC Olympia Pharmacy Dornier MedTech Olympus America DuPage Medical Group OPKO Health, Inc EDAP TMS Pacific Edge Diagnostics USA Ltd. Endo Pharmaceuticals PathRight Medical Exosome Diagnostics, Inc Photocure Ferring Pharmaceuticals Retrophin GE Healthcare Richard Wolf Medical Instruments, Corp. Genomic Health TOLMAR Pharmaceuticals HealthTronics, Inc. United Medical Systems Henry Ford Health System University Compounding Pharmacy Hitachi Healthcare University Compounding Pharmacy of Michigan Indiana University Health Uromedica Back to Table of Contents 8 Industry Satellite Symposium Events THURSDAY, SEPTEMBER 6, 2018 12:00 p.m. - 1:15 p.m. Industry Sponsored Lunch Symposium Location: Crystal Room "A Treatment Option for Certain Patients With Locally Advanced or Metastatic Urothelial Carcinoma" Vahan Kassabian, MD Atlanta, GA 12:00 p.m. - 1:15 p.m. Industry Sponsored Lunch Symposium Location: Regent Room FRIDAY, SEPTEMBER 7, 2018 12:00 p.m. - 1:15 p.m. Industry Sponsored Lunch Symposium Location: Crystal Room “A Treatment Option for Castration-Resistant Prostate Cancer (CRPC)” Paul Sieber, MD Lancaster Urology Lancaster, PA 12:00 p.m. - 1:15 p.m.
Load more

Recommended publications
  • Understanding Icd-10-Cm and Icd-10-Pcs 3Rd Edition Download Free
    UNDERSTANDING ICD-10-CM AND ICD-10-PCS 3RD EDITION DOWNLOAD FREE Mary Jo Bowie | 9781305446410 | | | | | International Classification of Diseases, (ICD-10-CM/PCS) Transition - Background Palmer B. Manual placenta removal. A: Understanding ICD-10-CM and ICD-10-PCS 3rd edition International Classification of Diseases ICD is a common framework and language to report, compile, use and compare health information. Psychoanalysis Adlerian therapy Analytical therapy Mentalization-based treatment Transference focused psychotherapy. Hysteroscopy Vacuum aspiration. Every code begins with an alpha character, which is indicative of the chapter to which the code is classified. Search Compliance Understanding BC, resilience standards and how to comply Follow these nine steps to first identify relevant business continuity and resilience standards and, second, launch a successful While many coders use ICD lookup software to help them, referring to an ICD code book is invaluable to build an understanding of the classification system. Pregnancy test Leopold's maneuvers Prenatal testing. Endoscopy : Colonoscopy Anoscopy Capsule endoscopy Enteroscopy Proctoscopy Sigmoidoscopy Abdominal ultrasonography Defecography Double-contrast barium enema Endoanal ultrasound Enteroclysis Lower gastrointestinal series Small-bowel follow-through Transrectal ultrasonography Virtual colonoscopy. Psychosurgery Lobotomy Bilateral cingulotomy Multiple subpial transection Hemispherectomy Corpus callosotomy Anterior temporal lobectomy. While codes in sections are structured similarly to the Medical and Surgical section, there are a few exceptions. Send Feedback Do you have Understanding ICD-10-CM and ICD-10-PCS 3rd edition on the new website? Help Learn to edit Community portal Recent changes Upload file. D Radiation oncology. Stem cell transplantation Hematopoietic stem cell transplantation. The primary distinctions are:. Palmer Joseph C.
    [Show full text]
  • Urologic Malignancies
    Scope • Anatomy •Urologic Malignancies • Trauma • Emergencies • Infections • Lower Urinary Tract Obstruction • Upper Urinary Tract Obstruction • Pediatric Urology • Key Points Emmanuel L. Barcenas Urologist/Urologic Surgeon Urology Specialty Group and Associates • Doctor of Medicine, SWU • Diplomate, Philippine Board of Surgery and the Philippine Board of Urology • Fellow, Philippine Urological Association • Fellow, Philippine College of Surgeons • Member, Philippine Endourological Society • Member, Phillippine Society of Urooncologists Urologic Malignancies Urologic Malignancies •Bladder Cancer •Testicular Cancer •Kidney Cancer •Prostate Cancer Urothelial Tumors of the UB •Transitional cell epithelium lines the urinary tract from the renal pelvis, ureter, urinary bladder, and the proximal two-thirds of the urethra •Tobacco use is the most frequent risk factor (50% in men and 40% in women), followed by occupational exposure to various carcinogenic materials such as automobile exhaust or industrial solvents. Detection of Urothelial Cancer •Painless gross hematuria occurs in 85% of patients & requires a complete evaluation that includes cystoscopy, urine cytology, CT scan, & a PSA. •Recurrent or significant hematuria (>3 RBC’s/HPF on 3 urinalysis, a single urinalysis with >100 RBCs, or gross Hematuria) is associated with significant renal or urologic lesion in 9.1% Detection of Urothelial Cancer • Patients with microscopic hematuria require a full evaluation, but low-risk patients do not require repeat evaluations. • High-risk individuals primarily are those with a smoking history & should be evaluated every 6 months. • The level of suspicion for urogenital neoplasms in patients with isolated painless hematuria and nondysmorphic RBCs increases with age. • White light cystoscopy with random bladder biopsies is the gold standard for tumor detection History & Staging •Low-grade papillary lesions are likely to recur in up to 60% of patients but invade in less than 10% of cases.
    [Show full text]
  • Guidelines on Testicular Cancer
    GUIDELINES ON TESTICULAR CANCER (Limited text update March 2015) P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg Eur Urol 2011 Aug;60(2):304-19 Introduction Compared with other types of cancer, testicular cancer is relatively rare accounting for approximately 1-1.5% of all cancers in men. Nowadays, testicular tumours show excellent cure rates, mainly due to early diagnosis and their extreme chemo- and radiosensitivity. Staging and Classification Staging For an accurate staging the following steps are necessary: Postorchiectomy half-life kinetics of serum tumour markers. The persistence of elevated serum tumour markers after orchiectomy may indicate the presence of disease, while their normalisation does not necessarily mean absence of tumour. Tumour markers should be assessed until they are normal, as long as they follow their half-life kinetics and no metastases are revealed. A chest CT scan should be routinely performed in patients diagnosed with non-seminomatous germ cell tumours (NSGCT), because in up to 10% of cases, small subpleural nodes may be present that are not visible radiologically. 110 Testicular Cancer Recommended tests for staging at diagnosis Test Recommendation GR Serum tumour markers Alpha-fetoprotein A hCG LDH Abdominopelvic CT All patients A Chest CT All patients A Testis ultrasound (bilateral) All patients A Bone scan or MRI columna In case of symptoms Brain scan (CT/MRI) In case of symptoms and patients with meta- static disease with mul- tiple lung metastases and/or high beta-hCG values. Further investigations Fertility investigations: B Total testosterone LH FSH Semen analysis Sperm banking should be offered.
    [Show full text]
  • Paratesticular Metastasis of High Grade Prostate Cancer Clinically
    CASE REPORT Urooncology Doi: 10.4274/jus.481 Journal of Urological Surgery, 2017;4:26-28 Paratesticular Metastasis of High Grade Prostate Cancer Clinically Mimicking Hemato/Pyo-hydrocele Paratestiküler Metastazla Presente Olan Yüksek Dereceli Prostat Adenokarsinomu Hikmet Köseoğlu1, Şemsi Altaner2 1Başkent University Faculty of Medicine, Department of Urology, İstanbul, Turkiye 2Başkent University Faculty of Medicine, Department of Pathology, İstanbul, Turkiye Abstract Secondary metastatic lesions of the testicles are very rare and they originate mainly from prostate adenocarcinoma. They are generally diagnosed incidentally, however, they very rarely manifest as a palpable testicular mass. In this paper, we present, a case of paratesticular metastasis from high- grade prostate cancer clinically mimicking pyo-/hemato-/hydrocele. A 75-year-old man, who had been followed up elsewhere for a huge hydrocele based on scrotal Doppler ultrasonography and scrotal magnetic resonance imaging reporting no suspicion for malignancy, but a pyo-/hemato-/ hydrocele was determined to have testicular metastasis originating from prostate adenocarcinoma. Keywords: Hydrocele, testis, neoplasm metastasis, prostate, adenocarcinoma Öz Testisin metastatik lezyonları oldukça nadirdir ve çoğunlukla prostat kanserinden köken almaktadırlar. Genellikle rastlantısal olarak tanı alırlar; ancak çok nadir testiste palpe edilebilen kitle ile belirti verirler. Bu olgu bildirisinde klinik olarak pyo-/hemato-/hidrosel olarak izlenen olguda yüksek dereceli prostat kanseri metastazı
    [Show full text]
  • (A) Administrative Information Advanced Urooncology Course URL
    Course SPECIFICATION Faculty of Medicine- Mansoura University Urology (A) Administrative information (1) Programme offering the course: URL 623 (2) Department offering the programme: Urology Department (3) Department responsible for teaching the Urology Department course: (4) Part of the programme: Prof. Dr. Ahmed Mosbah (5) Date of approval by the Department`s council May, 2016 (6) Date of last approval of programme 9/8/2016 specification by Faculty council (7) Course title: Advanced urooncology course (8) Course code: URL 623 AUO (9) Credit hours 1 hour (10) Total teaching hours: 14 theoretical hours 1 (B) Professional information (1) Programme Aims: The general aim of the course is to provide postgraduate students with the knowledge, skills and some attitudes necessary to make an essential urologic framework of the urologist including awareness of the common urologic emergencies. 1- Enlist the etiology, pathology, diagnosis and treatment of urologic tumours. 2- Describe emergencies related to urologic oncology and how to deal with it. 3- Define the steps of performing radical nephrectomy, radical cystectomy, radical prostatectomy, high inguinal orchiectomy and penectomy. 4- Practice urologic oncology in the outpatient clinic under supervision by the faculty members. 5- Study how to evaluate the urologic oncology patient. 6- Design a research proposal and how to implement and publish it. 7- Describe different modalities of treatment of urologic tumours other than surgery. (2) Intended Learning Outcomes (ILOs): Intended learning outcomes (ILOs); Are four main categories: knowledge & understanding to be gained, intellectual qualities, professional/practical and transferable skills. On successful completion of the programme, the candidate will be able to: A- Knowledge and Understanding K1 Biological behavior of all urologic tumours.
    [Show full text]
  • Castrating Pedophiles Convicted of Sex Offenses Against Children: New Treatment Or Old Punishment
    SMU Law Review Volume 51 Issue 2 Article 4 1998 Castrating Pedophiles Convicted of Sex Offenses against Children: New Treatment or Old Punishment William Winslade T. Howard Stone Michele Smith-Bell Denise M. Webb Follow this and additional works at: https://scholar.smu.edu/smulr Recommended Citation William Winslade et al., Castrating Pedophiles Convicted of Sex Offenses against Children: New Treatment or Old Punishment, 51 SMU L. REV. 349 (1998) https://scholar.smu.edu/smulr/vol51/iss2/4 This Article is brought to you for free and open access by the Law Journals at SMU Scholar. It has been accepted for inclusion in SMU Law Review by an authorized administrator of SMU Scholar. For more information, please visit http://digitalrepository.smu.edu. CASTRATING PEDOPHILES CONVICTED OF SEX OFFENSES AGAINST CHILDREN: NEW TREATMENT OR OLD PUNISHMENT? William Winslade* T. Howard Stone** Michele Smith-Bell*** Denise M. Webb**** TABLE OF CONTENTS I. INTRODUCTION ........................................ 351 II. PEDOPHILIA AND ITS TREATMENT ................. 354 A. THE NATURE OF PEDOPHILIA ......................... 355 1. Definition of Pedophilia ........................... 355 2. Sex Offenses and Sex Offenders ................... 357 a. Incidence of Sex Offenses ..................... 357 b. Characteristics of and Distinctions Among Sex O ffenders ..................................... 360 B. ETIOLOGY AND TREATMENT .......................... 364 1. Etiology and Course of Pedophilia................. 364 2. Treatment ......................................... 365 a. Biological of Pharmacological Treatment ...... 366 * Program Director, Program on Legal & Ethical Issues in Correctional Health, In- stitute for the Medical Humanities, James Wade Rockwell Professor of Philosophy of Medicine, Professor of Preventive Medicine & Community Health, and Professor of Psy- chiatry & Behavioral Sciences, University of Texas Medical Branch, Galveston, Texas; Dis- tinguished Visiting Professor of Law, University of Houston Health Law & Policy Institute.
    [Show full text]
  • Laboratory Guide 2021 Valid from 1St January 2021 Cover: Daniel Odukoya, BMS, Laboratory Supervisor Within Molecular Pathology Handling PCR Samples
    Laboratory Guide 2021 Valid from 1st January 2021 Cover: Daniel Odukoya, BMS, Laboratory Supervisor within Molecular Pathology handling PCR samples. TAP4557/22-11-20/V3 Laboratory Guide 2021 Valid from 1st January 2021 TDL Customer Charter We are committed to being the most helpful pathology service in the UK. Our goal is always to provide a high level of service to our customers, who request pathology services, for their patients. This is a philosophy shared by all Sonic Healthcare Pathology practices. We are medically led, and patients are our first concern. We always try to look to improve our operational expertise, and we strive to provide professional leadership within our specialities. We promise to provide easy access to our pathology services • We will always provide a friendly, helpful service. • Our automated laboratory departments operate 24 hours a day, 7 days a week, and we aim to achieve, or improve, our published turnaround times. • Our medical consultants and laboratory teams are available to provide additional clarification, advice or information for tests or results. We promise to help you • We invest in technical and operational excellence, with an extensive test repertoire, to ensure access to a leading-edge laboratory service. • We return results using the reporting method choice, in an as organised and safe way as possible. We promise to support the communities we work in • We do our utmost to provide a service, even during extreme external disruptions beyond our control. • We are committed to our staff’s continued professional development. • We have an organised programme to provide young people with work experience.
    [Show full text]
  • Effective for Cases Diagnosed January 1, 2016 and Later
    POLICY AND PROCEDURE MANUAL FOR REPORTING FACILITIES May 2016 Effective For Cases Diagnosed January 1, 2016 and Later Indiana State Cancer Registry Indiana State Department of Health 2 North Meridian Street, Section 6-B Indianapolis, IN 46204-3010 TABLE OF CONTENTS INDIANA STATE DEPARTMENT OF HEALTH STAFF ............................................................................. viii INDIANA STATE DEPARTMENT OF HEALTH CANCER REGISTRY STAFF .......................................... ix ACKNOWLEDGMENTS ................................................................................................................................ x INTRODUCTION ........................................................................................................................................... 1 A. Background ..................................................................................................................................... 1 B. Purpose .......................................................................................................................................... 1 C. Definitions ....................................................................................................................................... 1 D. Reference Materials........................................................................................................................ 1 E. Consultation .................................................................................................................................... 2 F. Output ............................................................................................................................................
    [Show full text]
  • An Overview of the Management of Post-Vasectomy Pain Syndrome Male Fertility
    [Downloaded free from http://www.ajandrology.com on Thursday, March 31, 2016, IP: 208.78.175.61] Asian Journal of Andrology (2016) 18, 1–6 © 2016 AJA, SIMM & SJTU. All rights reserved 1008-682X www.asiaandro.com; www.ajandrology.com Open Access INVITED REVIEW An overview of the management of post-vasectomy pain syndrome Male Fertility Wei Phin Tan, Laurence A Levine Post-vasectomy pain syndrome remains one of the more challenging urological problems to manage. This can be a frustrating process for both the patient and clinician as there is no well-recognized diagnostic regimen or reliable effective treatment. Many of these patients will end up seeing physicians across many disciplines, further frustrating them. The etiology of post-vasectomy pain syndrome is not clearly delineated. Postulations include damage to the scrotal and spermatic cord nerve structures via inflammatory effects of the immune system, back pressure effects in the obstructed vas and epididymis, vascular stasis, nerve impingement, or perineural fibrosis. Post-vasectomy pain syndrome is defined as at least 3 months of chronic or intermittent scrotal content pain. This article reviews the current understanding of post-vasectomy pain syndrome, theories behind its pathophysiology, evaluation pathways, and treatment options. Asian Journal of Andrology (2016) 18, 1–6; doi: 10.4103/1008-682X.175090; published online: 4 March 2016 Keywords: epididymectomy; microdenervation; orchalgia; post-vasectomy pain management; post-vasectomy pain syndrome; testicular pain; vasectomy reversal; vaso-vasostomy INTRODUCTION to PVPS using the Mesh Words “Post-vasectomy Pain Syndrome,” Vasectomies are one of the most common urological procedures performed “Post Vasectomy Pain Syndrome,” “Microdenervation of Spermatic by urologists worldwide.
    [Show full text]
  • Erectile Dysfunction in Family Practice: The
    ERECTILE DYSFUNCTION IN FAMILY PRACTICE: THE PREVALENCE AND CLINICAL CORRELATES AMONG ADULT MALE PATIENTS PRESENTING AT THE GENERAL OUTPATIENTS DEPARTMENT, UNIVERSITY COLLEGE HOSPITAL, IBADAN. A DISSERTATION SUBMITTED TO THE FACULTY OF FAMILY MEDICINE OF THE NATIONAL POSTGRADUATE MEDICAL COLLEGE OF NIGERIA IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE FELLOWSHIP IN FAMILY MEDICINE BY ADEBUSOYE, LAWRENCE ADEKUNLE MB;BS(Ibadan) MAY 2008 ETHICAL APPROVAL 2 DEDICATION This dissertation is dedicated to Almighty God, my darling and supportive wife Adekemi and my children: Oluwadamilola, Oluwafemi and Oluwatobi. 3 CERTIFICATION We certify that this study has been carried out by Dr. LAWRENCE ADEKUNLE ADEBUSOYE in the General Outpatients’ Department, University College Hospital, Ibadan, Nigeria. Supervisors: ___________________________________ Dr M.M.A. Ladipo MB;BS (Ib), FMCGP (Nig), FWACP (FM). Consultant Family Physician Head, General Outpatients’ Department University College Hospital, Ibadan, Nigeria. _______________________________ Mr E.O. Olapade-olaopa FWACS, FRCS Consultant urologist Department of Surgery University College Hospital, Ibadan, Nigeria. 4 DECLARATION I do hereby declare that this work has not been presented to any other College or a body for examination purposes or elsewhere for publication. _________________________________ ADEBUSOYE, LAWRENCE ADEKUNLE MB,BS (Ibadan) 5 ACKNOWLEDGEMENT My gratitude goes to the Almighty God who sustained me through the Postgraduate programme in Family Medicine. I wish to express my sincere gratitude to my supervisors Dr M.M.A. Ladipo, trainer, mentor, and the Head of General Outpatients’ department of the University College Hospital, Ibadan and Mr E.O. Olapade-Olaopa for their support, guidance and encouragement. I acknowledge with gratitude Drs E. Ibeneme, I. Ajayi and A.
    [Show full text]
  • A Retrospective Study of Cryptorchidectomy in Horses: Diagnosis, Treatment, Outcome and Complications in 70 Cases
    animals Article A Retrospective Study of Cryptorchidectomy in Horses: Diagnosis, Treatment, Outcome and Complications in 70 Cases Paola Straticò, Vincenzo Varasano, Giulia Guerri * , Gianluca Celani , Adriana Palozzo and Lucio Petrizzi Faculty of Veterinary Medicine, University of Teramo, Località Piano D’Accio, 64100 Teramo, Italy; [email protected] (P.S.); [email protected] (V.V.); [email protected] (G.C.); [email protected] (A.P.); [email protected] (L.P.) * Correspondence: [email protected] Received: 26 November 2020; Accepted: 17 December 2020; Published: 21 December 2020 Simple Summary: Cryptorchidism is the failure of one or both testes to descend into the scrotum and is considered to be one of the most common developmental disorders in horses. The aim of the study was to review medical records of horses referred for uni- or bilateral cryptorchidism. It was observed that the Western Riding horse breeds were the most affected, and that left abdominal and right inguinal retentions were the most frequent. Transabdominal ultrasound was the most reliable diagnostic tool to localize the retained testis. Standing laparoscopic and open inguinal cryptorchidectomy were elected as the surgical treatment of choice, in case of abdominal retention and inguinal retention respectively. For incomplete abdominal retention, laparoscopy was the preferred treatment, even though an open inguinal approach was a viable option for the concurrent removal of the descended testis. Abstract: The aim of the study was to investigate the breed predisposition and the diagnostic and surgical management of horses referred for cryptorchidism. The breed, localization of retained testis, diagnosis, type of surgical treatment and complications were analyzed.
    [Show full text]
  • Paediatric Urology
    EAU Guidelines on Paediatric Urology C. Radmayr (Chair), G. Bogaert, H.S. Dogan, J.M. Nijman (Vice-chair), Y.F.H. Rawashdeh, M.S. Silay, R. Stein, S. Tekgül Guidelines Associates: L.A. ‘t Hoen, J. Quaedackers, N. Bhatt © European Association of Urology 2021 TABLE OF CONTENTS PAGE 1. INTRODUCTION 9 1.1 Aim 9 1.2 Panel composition 9 1.3 Available publications 9 1.4 Publication history 9 1.5 Summary of changes 9 1.5.1 New recommendations 10 2. METHODS 11 2.1 Introduction 11 2.2 Peer review 11 3. THE GUIDELINE 11 3.1 Phimosis 11 3.1.1 Epidemiology, aetiology and pathophysiology 12 3.1.2 Classification systems 12 3.1.3 Diagnostic evaluation 12 3.1.4 Management 12 3.1.5 Complications 13 3.1.6 Follow-up 13 3.1.7 Summary of evidence and recommendations for the management of phimosis 13 3.2 Management of undescended testes 13 3.2.1 Background 13 3.2.2 Classification 13 3.2.2.1 Palpable testes 14 3.2.2.2 Non-palpable testes 14 3.2.3 Diagnostic evaluation 15 3.2.3.1 History 15 3.2.3.2 Physical examination 15 3.2.3.3 Imaging studies 15 3.2.4 Management 15 3.2.4.1 Medical therapy 15 3.2.4.1.1 Medical therapy for testicular descent 15 3.2.4.1.2 Medical therapy for fertility potential 16 3.2.4.2 Surgical therapy 16 3.2.4.2.1 Palpable testes 16 3.2.4.2.1.1 Inguinal orchidopexy 16 3.2.4.2.1.2 Scrotal orchidopexy 17 3.2.4.2.2 Non-palpable testes 17 3.2.4.2.3 Complications of surgical therapy 17 3.2.4.2.4 Surgical therapy for undescended testes after puberty 17 3.2.5 Undescended testes and fertility 18 3.2.6 Undescended testes and malignancy 19 3.2.7 Summary
    [Show full text]